Study of Neo-adjuvant RO7009789 Alone or Neo-adjuvant RO7009789 Plus Nab-Paclitaxel and Gemcitabine Followed by Adjuvant RO7009789 Plus Nab-Paclitaxel and Gemcitabine for Patients With Newly Diagnosed Resectable Pancreatic Carcinoma
Clinical trial NCT02588443 · COMPLETED
Trial details
- NCT number
- NCT02588443
- Sponsor
- Abramson Cancer Center at Penn Medicine
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2015-10-01
- Primary completion
- 2018-11-01
- Enrollment
- 19
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.